M1 Kliniken AG Reports Significant EBIT Growth Amidst Strategic Expansion

M1 Kliniken AG has announced a robust 11% growth in EBIT, reaching EUR 24.5 million for the first nine months of 2025. Earnings per share rose to EUR 0.86. The company attributes these gains to ongoing efficiency measures and expanding medical capacities. Group revenue increased by 6.7% to EUR 274.3 million.

The Beauty segment served as the primary growth driver, with a 9.5% rise in revenue to EUR 77.8 million and a 29.7% increase in EBIT to EUR 21.1 million. The Trading segment saw a 6% revenue boost but a decrease in EBIT by 41.4% to EUR 3.4 million. Additionally, M1 Kliniken AG finalized an agreement to sell HAEMATO Pharm GmbH to PHOENIX group, aligning with its strategic focus on medical aesthetics.

M1 Kliniken AG continues to expand its network of clinics, aiming to increase its EBIT margin to at least 20% by 2029. The company remains committed to establishing itself as a global leader in aesthetic medicine.